Nonresponse to 18-month lamivudine monotherapy in chronic hepatitis B patients with dual genotype B and C infection and acute exacerbation.
Molecular epidemiologic studies have indicated the possible existence of mixed infection of different hepatitis B virus (HBV) genotypes in chronic hepatitis B (CH-B) carriers, but the effect of dual HBV genotype B and C infection on the efficacy of lamivudine therapy remains unclear. We report four CH-B patients with dual HBV genotype B and C infection and acute exacerbation who received lamivudine monotherapy for about 18 months. None of them had achieved a sustained response at the end of the 18-month trial of treatment.
Sheu
Ming-Jen
MJ
Department of Internal Medicine, Division of Hepatogastroenterology, Chi Mei Medical Center, Tainan, Taiwan.
Lin
Ching-Yih
CY
Sun
Chi-Shu
CS
Kuo
Hsing-Tao
HT
Koay
Lok-Beng
LB
Lee
Chuan
C
Chen
Jyh-Jou
JJ
Tang
Ling-Yu
LY
Tsai
Sun-Lung
SL
D000208:Acute Disease; D000998:Antiviral Agents / Q000627:therapeutic use*; D004279:DNA, Viral / Q000097:blood; D005838:Genotype; D006515:Hepatitis B virus / Q000145:classification*; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*
D000998:Antiviral Agents; D004279:DNA, Viral; D019259:Lamivudine